--- title: Insights | Carolina Bonifacio description: Carolina Bonifacio is a seasoned pharmaceutical professional with over 20 years of experience in the industry, specializing in both sterile and oral solid dosage forms. She has extensive expertise in handling highly potent compounds and currently leads the Development teams at Siegfried’s Spanish finished product sites in Barberà del Vallès and El Masnou. Before joining Siegfried, Carolina held various positions of increasing responsibility at Novartis, focusing on technology transfer and scale-up processes. She holds a Pharmacy degree from the University of Salamanca, Spain, and a Master’s degree in Pharmaceutical Technology and Industrial Pharmacy from the University of Barcelona. --- This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) [Company](https://www.siegfried.ch/company/) Company [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) Offering [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) Sustainability [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights) [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) What are you looking for? [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) [Company](https://www.siegfried.ch/company/) [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights) - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) # Insights ## See our event recap Filter by tags [Technology](https://content.siegfried.ch/insights/tag/technology) [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Sustainability](https://content.siegfried.ch/insights/tag/sustainability) [Drug Products](https://content.siegfried.ch/insights/tag/drug-products) [Regulatory support](https://content.siegfried.ch/insights/tag/regulatory-support) [Technology](https://content.siegfried.ch/insights/tag/technology) [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Sustainability](https://content.siegfried.ch/insights/tag/sustainability) [Drug Products](https://content.siegfried.ch/insights/tag/drug-products) [Regulatory support](https://content.siegfried.ch/insights/tag/regulatory-support) [Oral solid dosage form](https://content.siegfried.ch/insights/tag/oral-solid-dosage-form) [Scale-up](https://content.siegfried.ch/insights/tag/scale-up) [Dosage Form](https://content.siegfried.ch/insights/tag/dosage-form) [Fill-finish](https://content.siegfried.ch/insights/tag/fill-finish) [Pharmaceutical Manufacturing](https://content.siegfried.ch/insights/tag/pharmaceutical-manufacturing) [Pre-filled syringes](https://content.siegfried.ch/insights/tag/pre-filled-syringes) NEW 11/10/2023 ### Safety first: Considerations when formulating high potency compounds [Read article](https://content.siegfried.ch/insights/safety-first-considerations-when-formulating-high-potency-compounds) Recent #### [Sep 28, 2026 Drug Products Pharmaceutical Manufacturing Where pre-filled syringe tech transfers go wrong](https://content.siegfried.ch/insights/where-pre-filled-syringe-tech-transfers-go-wrong) #### [Sep 28, 2026 Drug Products Oral solid dosage form Accelerating early-stage CMC development for oral drug products](https://content.siegfried.ch/insights/accelerating-early-stage-cmc-development-for-oral-drug-products-1) #### [Aug 19, 2026 Early-phase development Regulatory support More than compliance: Managing the challenges of controlled substance manufacturing](https://content.siegfried.ch/insights/more-than-compliance-managing-the-challenges-of-controlled-substance-manufacturing) #### Subscribe for more expert insights   All posts ### [Nov 10, 2023 Safety first: Considerations when formulating high potency compounds](https://content.siegfried.ch/insights/safety-first-considerations-when-formulating-high-potency-compounds) Oct 30, 2025 ### Video: Insights from Chief Scientific Officer Stefan Randl at CPHI Frankfurt 2025 Sign up to stay up to date on Siegfried and our business performance. expect more **Siegfried AG** Untere Brühlstrasse 4 4800 Zofingen, Switzerland [+41 62 746 11 11](tel:+41627461111) [Get in touch](https://www.siegfried.ch/contact-us/) #### About us - [Our company](https://www.siegfried.ch/company/) - [Sustainability](https://www.siegfried.ch/sustainability/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Careers](https://www.siegfried.ch/careers/) #### Helpful resources - [Expert insights](https://content.siegfried.ch/insights) - [News archive](https://www.siegfried.ch/news-archive/) - [Reports](https://www.siegfried.ch/investors/investors-download-center-2025/) - [Terms and conditions](https://www.siegfried.ch/terms-and-conditions/) #### Offering - [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) - [Drug Products](https://www.siegfried.ch/offering/drug-products/) - [Technologies](https://www.siegfried.ch/technologies/) 2026 © Siegfried Holding AG - [Privacy Policy](https://www.siegfried.ch/privacy-policy/) - [Legal disclaimer](https://www.siegfried.ch/legal-disclaimer/) - [Imprint](https://www.siegfried.ch/imprint/) ```json { "@context" : "https://schema.org", "@type" : "VideoObject", "contentUrl" : "https://143616667.fs1.hubspotusercontent-eu1.net/hubfs/143616667/Peter%20-%20Video%2001%20Final%20v2.mp4", "dateModified" : "2025-10-31T17:20:09.538Z", "duration" : "PT2M16S", "height" : 1080, "name" : "Peter - Video 01 Final v2", "thumbnailUrl" : "https://143616667.fs1.hubspotusercontent-eu1.net/hubfs/143616667/Peter%20-%20Video%2001%20Final%20v2.mp4/medium.jpg", "uploadDate" : "2025-10-28T21:59:19.239Z", "width" : 1920 } ```